Browse by author
Lookup NU author(s): Dr Ken BakerORCiD,
Professor Andrew GenneryORCiD,
Dr Shanti Mahabir,
Dr Catherine Stroud
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2020 American Academy of Allergy, Asthma & ImmunologyBackground: As of November 2020, severe acute respiratory syndrome coronavirus 2 has resulted in 55 million infections worldwide and more than 1.3 million deaths from coronavirus disease 2019 (COVID-19). Outcomes following severe acute respiratory syndrome coronavirus 2 infection in individuals with primary immunodeficiency (PID) or symptomatic secondary immunodeficiency (SID) remain uncertain. Objectives: We sought to document the outcomes of individuals with PID or symptomatic SID following COVID-19 in the United Kingdom. Methods: At the start of the COVID-19 pandemic, the United Kingdom Primary Immunodeficiency Network established a registry of cases to collate the nationwide outcomes of COVID-19 in individuals with PID or symptomatic SID and determine risk factors associated with morbidity and mortality from COVID-19 in these patient groups. Results: A total of 100 patients had been enrolled by July 1, 2020, 60 with PID, 7 with other inborn errors of immunity including autoinflammatory diseases and C1 inhibitor deficiency, and 33 with symptomatic SID. In individuals with PID, 53.3% (32 of 60) were hospitalized, the infection-fatality ratio was 20.0% (12 of 60), the case-fatality ratio was 31.6% (12 of 38), and the inpatient mortality was 37.5% (12 of 32). Individuals with SID had worse outcomes than those with PID; 75.8% (25 of 33) were hospitalized, the infection-fatality ratio was 33.3% (11 of 33), the case-fatality ratio was 39.2% (11 of 28), and inpatient mortality was 44.0% (11 of 25). Conclusions: In comparison to the general population, adult patients with PID and symptomatic SID display greater morbidity and mortality from COVID-19. This increased risk must be reflected in public health guidelines to adequately protect vulnerable patients from exposure to the virus.
Author(s): Shields AM, Burns SO, Savic S, Richter AG, Anantharachagan A, Arumugakani G, Baker K, Bahal S, Bermingham W, Bhole M, Boules E, Bright P, Burns S, Cleave B, Dempster J, Devlin L, Dhalla F, Drewe E, Duncan C, Dziadzio M, Elkhalifa S, Gennery A, Goddard S, Grigoriadou S, Hayman G, Herwadkar A, Huissoon A, Jain R, Jolles S, Johnston S, Leeman L, Mahabir S, MacLochlainn D, McDermott E, Misbah S, Morsi H, Murng S, Noorani S, O'Brien R, Patel S, Price A, Richter A, Seneviratne S, Shields A, Shrimpton A, Stroud C, Vaitla P, Verma N
Publication type: Article
Publication status: Published
Journal: Journal of Allergy and Clinical Immunology
Print publication date: 01/03/2021
Online publication date: 14/12/2020
Acceptance date: 02/12/2020
ISSN (print): 0091-6749
ISSN (electronic): 1097-6825
Publisher: Mosby Inc.
PubMed id: 33338534
Altmetrics provided by Altmetric